

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 3, 2021**

Axcelis Technologies, Inc.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction
of incorporation)

000-30941

(Commission
File Number)

34-1818596

(IRS Employer
Identification No.)

108 Cherry Hill Drive, Beverly, Massachusetts

(Address of principal executive offices)

01915

(Zip Code)

Registrant's telephone number, including area code: **(978) 787-4000**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2.):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value \$0.001 per share	ACLS	NASDAQ Global Select Market

Item 2.02 Results of Operations and Financial Condition

On November 3, 2021, Axcelis Technologies, Inc. (the “Company”) issued a press release regarding its financial results for its quarter ended September 30, 2021. The Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

<u>Exhibit No.</u>	<u>Description</u>
99.1 104	Press Release dated November 3, 2021. Filed herewith. Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 3, 2021

Axcelis Technologies, Inc.

By: /s/ KEVIN J. BREWER
Kevin J. Brewer
Executive Vice President
and Chief Financial Officer



News Release

AXCELIS ANNOUNCES FINANCIAL RESULTS FOR THIRD QUARTER 2021***The Company Reports Record Implant Systems Revenue and Backlog***

BEVERLY, Mass. — November 3, 2021—Axcelis Technologies, Inc. (Nasdaq: ACLS), a leading supplier of enabling ion implantation solutions for the semiconductor industry, today announced financial results for the third quarter ended September 30, 2021.

Highlights for the third quarter are as follows:

- The Company reported third quarter revenue of \$176.7 million, compared to \$147.3 million for the second quarter of 2021. This includes quarterly system revenues of \$126.2 million dollars, an implant systems record, compared to \$100.1 million in the second quarter.
- Operating profit for the quarter was \$36.4 million, compared to \$24 million for the second quarter.
- Net income for the quarter was \$27.5 million, or \$0.81 per diluted share, compared to net income of \$18.9 million, or \$0.55 per diluted share for the second quarter.
- Gross margin for the quarter was 43.3%, compared to 43.5% in the second quarter.
- Shipped full family of Purion SiC Power Series™ implanters to leading power device chipmakers located in Asia and Europe.
- Shipped multiple Purion™ high current and high energy implanters to a leading memory device manufacturer located in Asia.

President and CEO Mary Puma commented, “Axcelis delivered very strong third quarter financial performance driven by record implant systems revenue and solid gross margins. The mature and specialty markets, especially the implant-intensive power device segment, are generating significant market expansion. Axcelis is capitalizing on the strength of these segments with market leading Purion product extensions specifically designed to meet these customers’ requirements. The Company is well positioned for long-term, sustainable growth.”

Business Outlook

For the fourth quarter ending December 31, 2021, Axcelis expects revenues to be approximately \$190 million. Gross margin in the fourth quarter is expected to be approximately 41.5%. Fourth quarter operating profit is forecasted to be approximately \$37 million with earnings per diluted share of approximately \$0.84. The Company also expects to exceed \$640 million in revenue for the full year 2021.

News Release

Third Quarter 2021 Conference Call

The Company will host a call to discuss the results for the third quarter on Thursday, November 4, 2021 at 8:30 am ET. The call will be available to interested listeners via an audio webcast that can be accessed through the Investors page of Axcelis' website at www.axcelis.com, or by dialing 866.588.8911 (707.294.1561 outside North America). Participants calling into the conference call will be requested to provide the company name, Axcelis Technologies, and Audience Passcode: 4426677. Webcast replays will be available for 30 days following the call.

Safe Harbor Statement

This press release and the conference call contain forward-looking statements under the Private Securities Litigation Reform Act safe harbor provisions. These statements, which include our expectations for spending in our industry and guidance for future financial performance, are based on management's current expectations and should be viewed with caution. They are subject to various risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, many of which are outside the control of the Company, including that customer decisions to place orders or our product shipments may not occur when we expect, that orders may not be converted to revenue in any particular quarter, or at all, whether demand will continue for the semiconductor equipment we produce or, if not, whether we can successfully meet changing market requirements, and whether we will be able to maintain continuity of business relationships with and purchases by major customers. Increased competitive pressure on sales and pricing, increases in material and other production costs that cannot be recouped in product pricing and instability caused by changing global economic, political or financial conditions could also cause actual results to differ materially from those in our forward-looking statements. These risks and other risk factors relating to Axcelis are described more fully in the most recent Form 10-K filed by Axcelis and in other documents filed from time to time with the Securities and Exchange Commission.

About Axcelis:

Axcelis (Nasdaq: ACLS), headquartered in Beverly, Mass., has been providing innovative, high-productivity solutions for the semiconductor industry for over 40 years. Axcelis is dedicated to developing enabling process applications through the design, manufacture and complete life cycle support of ion implantation systems, one of the most critical and enabling steps in the IC manufacturing process. Learn more about Axcelis at www.axcelis.com.

News Release

Company Contacts

Investor Relations:
Doug Lawson
978.787.9552

Editorial/Media:
Maureen Hart
978.787.4266

Axcelis Technologies, Inc.
Consolidated Statements of Operations
(In thousands, except per share amounts)
(Unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2021	2020	2021	2020
Revenue:				
Product	\$ 169,151	\$ 104,799	\$ 435,916	\$ 334,126
Services	7,543	5,606	20,828	18,235
Total revenue	<u>176,694</u>	<u>110,405</u>	<u>456,744</u>	<u>352,361</u>
Cost of revenue:				
Product	93,201	56,427	240,223	189,118
Services	6,981	5,817	19,560	17,634
Total cost of revenue	<u>100,182</u>	<u>62,244</u>	<u>259,783</u>	<u>206,752</u>
Gross profit	76,512	48,161	196,961	145,609
Operating expenses:				
Research and development	16,707	14,867	49,015	45,513
Sales and marketing	11,415	9,763	33,979	27,404
General and administrative	11,996	9,649	33,226	28,726
Total operating expenses	<u>40,118</u>	<u>34,279</u>	<u>116,220</u>	<u>101,643</u>
Income from operations	36,394	13,882	80,741	43,966
Other (expense) income:				
Interest income	51	106	124	658
Interest expense	(1,269)	(1,296)	(3,572)	(3,898)
Other, net	(963)	900	(2,131)	701
Total other expense	<u>(2,181)</u>	<u>(290)</u>	<u>(5,579)</u>	<u>(2,539)</u>
Income before income taxes	34,213	13,592	75,162	41,427
Income tax provision	6,698	2,807	12,261	6,119
Net income	<u>\$ 27,515</u>	<u>\$ 10,785</u>	<u>\$ 62,901</u>	<u>\$ 35,308</u>
Net income per share:				
Basic	<u>\$ 0.82</u>	<u>\$ 0.32</u>	<u>\$ 1.87</u>	<u>\$ 1.06</u>
Diluted	<u>\$ 0.81</u>	<u>\$ 0.32</u>	<u>\$ 1.83</u>	<u>\$ 1.04</u>
Shares used in computing net income per share:				
Basic weighted average common shares	<u>33,537</u>	<u>33,477</u>	<u>33,643</u>	<u>33,159</u>
Diluted weighted average common shares	<u>34,089</u>	<u>34,174</u>	<u>34,339</u>	<u>34,070</u>

Axcelis Technologies, Inc.
Consolidated Balance Sheets
(In thousands, except per share amounts)
(Unaudited)

	<u>September 30,</u> <u>2021</u>	<u>December 31,</u> <u>2020</u>
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 271,085	\$ 203,479
Accounts receivable, net	78,257	86,865
Inventories, net	196,812	161,076
Prepaid expenses and other current assets	23,990	19,371
Total current assets	<u>570,144</u>	<u>470,791</u>
Property, plant and equipment, net	32,921	29,840
Operating lease assets	8,106	4,542
Finance lease assets, net	19,563	20,544
Long-term restricted cash	756	753
Deferred income taxes	44,206	57,851
Other assets	35,282	40,303
Total assets	<u>\$ 710,978</u>	<u>\$ 624,624</u>
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	\$ 35,499	\$ 24,013
Accrued compensation	23,548	24,562
Warranty	5,741	4,280
Income taxes	623	654
Deferred revenue	54,502	21,221
Current portion of finance lease obligation	921	756
Other current liabilities	16,361	8,945
Total current liabilities	<u>137,195</u>	<u>84,431</u>
Long-term finance lease obligation	46,672	47,393
Long-term deferred revenue	3,738	1,837
Other long-term liabilities	11,694	9,361
Total liabilities	<u>199,299</u>	<u>143,022</u>
Stockholders' equity:		
Common stock, \$0.001 par value, 75,000 shares authorized; 33,406 shares issued and outstanding at September 30, 2021; 33,633 shares issued and outstanding at December 31, 2020	33	34
Additional paid-in capital	559,913	570,102
Accumulated deficit	(50,017)	(91,969)
Accumulated other comprehensive income	1,750	3,435
Total stockholders' equity	<u>511,679</u>	<u>481,602</u>
Total liabilities and stockholders' equity	<u>\$ 710,978</u>	<u>\$ 624,624</u>